Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07665268 · ClinicalTrials.gov registry record · Phase 4
Study Title: A Multicenter, Prospective, Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers.
A Phase 4 study, sponsored by Sequence LifeScience.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 2,000
- Enrollment target
NCT07665268: Recruiting Phase 4 study, sponsored by Sequence LifeScience.
NCT07665268 is a Phase 4 study that is actively recruiting participants, run by Sequence LifeScience. The registered enrollment target is 2,000 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (286% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07665268, a Phase 4 study, is actively recruiting participants, sponsored by Sequence LifeScience.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 2,000 participants
- Enrollment target
Study Summary
A multicenter prospective modified platform trial evaluating several cellular, acellular, and matrix like products and standard of care versus matched standard of care controls in the management of nonhealing pressure ulcers.
Primary Outcome
Determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing pressure ulcers with multiple CAMPs plus SOC versus matched SOC controls (mSOC) over 20 weeks using a modified platform trial design.
Interventions
- OTHER Activate™ Matrix + SOC
- OTHER AmnioDefend™ FT Matrix + SOC
- OTHER Palisade™ DM Matrix + SOC
- OTHER Sentry™ SL Matrix + SOC
- OTHER Shelter™ DM Matrix + SOC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2026-01-28 |
| Est. Completion | 2028-01-28 |
| Phase | Phase 4 |
What NCT07665268 shows while recruiting
NCT07665268 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (286% higher).
The record links to 0 conditions, and to 5 interventions - of which Activate™ Matrix + SOC is the first listed.
NCT07665268 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07665268 about?
NCT07665268 is a clinical study titled "Study Title: A Multicenter, Prospective, Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers.". A multicenter prospective modified platform trial evaluating several cellular, acellular, and matrix like products and standard of care versus matched standard of care controls in the management of nonhealing pressure ulcers.
What is the current status of trial NCT07665268?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 2,000 participants. The study started on 2026-01-28. Estimated completion is 2028-01-28.
What interventions are being tested in trial NCT07665268?
The interventions under investigation include: Activate™ Matrix + SOC (OTHER), AmnioDefend™ FT Matrix + SOC (OTHER), Palisade™ DM Matrix + SOC (OTHER), Sentry™ SL Matrix + SOC (OTHER), Shelter™ DM Matrix + SOC (OTHER).
Who is sponsoring clinical trial NCT07665268?
This trial is sponsored by Sequence LifeScience, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07665268's enrollment target sits among peer trials
2,000 37th of 2000 higher than 1,958 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI